Search

Purpose: To evaluate anatomic, functional success, results of scleral buckling surgery performed to rhegmatogenous retinal detachment cases and factors affecting the surgery results. Materials and Methods: Skleral buckling surgery was performed to 78 rhegmatogenous retinal detachment cases in our clinic between June 2005 and August 2011 and medical records of these cases were evaluated retrospectively. General characteristics of the patients, etiologic factors, anatomical and functional successes and possible factors those may have a role on these results were evaluated. Results: 45 of the eyes (57.7%) were phakic, 29 were pseudophakic (37.2%) and 4 of them were aphakic (5.1%). It was determined that phakic patients had both anatomically and functionlly more successful results. The short duration of the application time was found to be significant for functional success, but not to be effect for anatomical success (respectively p=0.003, p=0.127).. Before the surgery in 67 of the cases (85.9%), macula was inside the detachment area, in 11case (14.1%) macula was reattached. Macular involvement was compared for anatomic and functional success and no significant difference was established. After an average of 23.7 months follow-up; functional success in 47 (60.3%) cases and anatomic success in 66 (84.6%) cases were obtained. Conclusions: Best results may be obtained when the appropriate surgical method was performed on time with the use of appropriate material for the scleral buckling surgery of rhegmatogenous retinal detachment. [ABSTRACT FROM AUTHOR]

Purpose: To assess efficacy of three loading dose of bevacizumab in central diabetic macular edema. Materials and Methods: This retrospective study included 30 eyes of 23 patients who were given three loading doses of monthly intravitreal bevacizumab (1.25 mg/mL) for central DDME between February, 2019 and January, 2021. The study included treatment-naive eyes with best-corrected visual acuity (BCVA) ≥ least 5 letters at baseline. In all cases, central macular thickness (CMT) was measured using spectral-domain optical coherence tomography (SD-OCT: Spectralis, Heidelberg Engineering, Heidelberg, Germany). The BCVA was assessed using geometric chart at 4 meters. BCVA, CMT and intraocular pressure measurements as well as biomicroscopy and fundus examination were performed at each control visit. Primary efficacy outcome was visual acuity gain (in letters) and CMT reduction. Data were analyzed using Paired samples t test, ANOVA and Pearson's correlation analysis. Findings: Mean age was 59.0±8.1 years in the study population. Mean BCVA was 19.6±10.7 letters while mean CMT was 479.0±10.6 µm at baseline. The vision was improved to 22.8±10.1 letters (p=0.007) while mean CMT was decreased t0 453.9±137.9 µm (p=0.163) after first injection (Paired samples t test). The vision was improved to 25.1±9.4 letters (p=0.007) and mean CMT was decreased to 420.8±130.5 µm (p=0.016) after second injection; and 28.6±9.9 letters (p=0.000) and 393±146.0 µm (p=0.002) after third injection. The letter gain was 9 letters. It was found that ≥3 orders improvement was achieved in 9 eyes )30%) whereas 2 orders in 8 eyes (26.7%) and 1 order in 9 eyes (30.0%). There was no response or decreased vision in 4 eyes (13.3%). Conclusion: Treatment with three loading dose of monthly bevacizumab is an effective first-line treatment ensuring visual and anatomic improvement in DME. [ABSTRACT FROM AUTHOR]